2020•UrologiiaRequires access

Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction

A A Kaputovskij

Abstract

The lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are an important medical and social problem. Combination of LUTS and ED is usually underdiagnosed. Selective phosphodiesterase 5 inhibitors (PDE5I) are recommended for treatment of both conditions. The aim of this review is to identify the best PDE5I for simultaneous treatment LUTS and ED.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Tadalafil, Erectile dysfunction, Lower urinary tract symptoms, Medicine, Urology, cGMP-specific phosphodiesterase type 5, Hyperplasia, Urinary system